# Oorja Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oorja-bio

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.oorjabio.com/
- Total disclosed funding: $20M
- Latest round: Series A (May 19, 2026)
- Investors on record: 1

## About

Oorja Bio, Inc. is a Houston-based biopharmaceutical company specializing in innovative therapies for cardiopulmonary and fibrotic disorders, focusing on addressing the underlying causes of these diseases. Founded in 2023 by Sujay Kango, Founder & Chief Executive Officer; Janethe Pena, Co-Founder & Chief Medical Officer; and Connie Coulomb, Co-Founder & Chief Business Officer, Oorja Bio, Inc. operates in the biopharmaceutical industry and is dedicated to developing treatments for serious fibrotic diseases. The company is located in Houston, US and focuses primarily on clinical-stage drug development.. The current CEO is Sujay Kango. In May 2026, Oorja Bio, Inc. raised USD 30 million in series A funding led by Westlake village BioPartners. Oorja Bio specializes in developing innovative therapies specifically targeting cardiopulmonary and fibrotic disorders. Their core product, ORJ-001, is a first-in-class peptide therapeutic designed for subcutaneous administration aimed at treating idiopathic pulmonary fibrosis (IPF). ORJ-001 works by restoring the function of alveolar epithelial type 2 (AEC2) cells, promoting alveolar repair and reducing the inflammatory and fibrotic signaling associated with pulmonary fibrosis. This product is part of Oorja's clinical-stage pipeline and is aimed at patients in the United States and Europe suffering from serious fibrotic diseases.Oorja Bio operates primarily within a clinical development framework, focusing on partnerships and collaborations within the biopharmaceutical sector to generate revenue. The company engages in direct-to-consumer transactions for its therapies, leveraging clinical trial data to attract investors and potential partners. Their revenue structure includes milestone payments and royalties related to the development and commercialization of ORJ-001, though specific pricing plans for their products are not disclosed.In May 2026, Oorja Bio, Inc. raised USD 19.9 mn in Series A funding, which will be utilized to advance ORJ-001 and expand their therapeutic pipeline. The company plans to launch additional products addressing fibrotic diseases and aims to penetrate new markets in both the United States and Europe. This funding will support their initiatives to enhance product development and strengthen market presence.

## Funding rounds

- Series A, May 19, 2026, $20M — Westlake Village BioPartners

## Investors

- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A